CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0302 (clinicaltrials.gov NCT No: NCT01829711)
Title:A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Moxetumomab
Study Status:Open
Study Description:Why is this study being done?
Moxetumomab pasudotox is an investigational agent that was developed to target
a particular molecule, CD22, that can be found on the surface of cancer cells
and to selectively kill the cells that have the molecule. Moxetumomab
pasudotox has not been approved by the Food and Drug Administration (FDA);
however, in an early clinical study of 48 patients with hairy cell leukemia who
had not responded to standard therapy, it has been shown to eliminate (26
patients) or reduce (16 patients) tumor cells. Overall 114 patients, both
children and adults, have been treated with moxetumomab pasudotox with limited
side effects which are discussed in the risks section of the consent.

The purpose of this study is to find how effective moxetumomab pasudotox is at
eliminating tumor cells for at least 6 months.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Moxetumomab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:CTEP
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
Dept:Leukemia
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults